EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP

Jøran Hjelmesæth iD, Suhas Bhat, W Timothy Garvey, Kristoffer Jensen Kolnes, Jennifer Linge, Ildiko Lingvay iD, Niklas Kahr Rasmussen, Julio Rosenstock iD, Sean Wharton iD

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11653-11663

DOI: 10.1111/dom.71323 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 20.09.2026. Verfasst von Jøran Hjelmesæth und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust, Tønsberg, Norway. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Muscle, Skeletal, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To assess the effect of semaglutide on body composition and physical function. Materials and Methods The phase 3b STEP UP trial randomised adults with body mass index ≥ 30 kg/m 2 to once‐weekly subcutaneous semaglutide 7.2 mg, semaglutide 2.4 mg or placebo for 72 weeks. This prespecified secondary analysis assessed changes in MRI body composition and physical function.

Results

Of 1407 participants, 55 with a valid baseline scan were included (semaglutide 7.2 mg, n = 43, 2.4 mg, n = 6 [pooled semaglutide group, n = 49]; placebo, n = 6). Estimated treatment differences (95% confidence intervals; p ‐values) for absolute changes in adipose/muscle compartment volumes for the pooled semaglutide versus placebo group, respectively, were: −11.1 L (−16.5 to −5.7; p < 0.0001) for adipose body tissue, −1.5 L (−2.9 to −0.1; p = 0.04) for visceral adipose tissue, −1.7 L (−4.0 to 0.7; p = 0.16) for lean body tissue, −1.1 L (−2.3 to 0.1; p = 0.07) for thigh skeletal muscle volume and −0.92%‐points (−1.41 to −0.42; p = 0.001) for thigh muscle fat infiltration. Similar results were seen for relative changes in adipose/muscle compartment volumes. A sensitivity analysis for the semaglutide 7.2 mg group versus placebo showed similar results. A mean of 13 sit‐to‐stand repetitions in 30 s at baseline, and 15 repetitions at Week 72, was observed in the pooled semaglutide and placebo groups.

Conclusions

Semaglutide plus lifestyle intervention was associated with reductions in adipose tissue volume, skeletal muscle volume and skeletal muscle fat infiltration, with a preserved number of sit‐to‐stand repetitions. Further research to assess the impact of weight loss on skeletal muscle composition and function should be explored in the future. Trial Registration: ClinicalTrials.gov identifier NCT05646706

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesMuscle, SkeletalObesityAnti-Obesity AgentsHumansSemaglutideFemaleMaleMiddle AgedAdultThighBody CompositionMagnetic Resonance ImagingDouble-Blind MethodAdipose TissueWeight Loss

Stichwörter der Autor:innen

GLP‐1 analogantiobesity drugclinical trialrandomised trialsemaglutideweight management

Substanzen

SemaglutideGlucagon-Like PeptidesAnti-Obesity Agents

Autor:innen und Institutionen

  • Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust, Tønsberg, Norway.
  • Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Novo Nordisk Global Business Services, Bangalore, India.
  • University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Novo Nordisk A/S, Søborg, Denmark.
  • AMRA Medical AB, Linköping, Sweden.

ORCID-Profile: Jøran Hjelmesæth, Ildiko Lingvay, Julio Rosenstock, Sean Wharton

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Hjelmesæth, J., Bhat, S., Garvey, W. T., Kolnes, K. J., Linge, J., Lingvay, I., Rasmussen, N. K., Rosenstock, J., & Wharton, S. (2026). Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP. Diabetes, Obesity and Metabolism, 28(12), 11653-11663. https://doi.org/10.1111/dom.71323

Vancouver

Hjelmesæth J, Bhat S, Garvey WT, Kolnes KJ, Linge J, Lingvay I, et al. Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP. Diabetes, Obesity and Metabolism. 2026;28(12):11653-11663. doi:10.1111/dom.71323

BibTeX
@article{Hjelmesth2026,
  author = {Hjelmesæth, Jøran and Bhat, Suhas and Garvey, W Timothy and Kolnes, Kristoffer Jensen and Linge, Jennifer and Lingvay, Ildiko and Rasmussen, Niklas Kahr and Rosenstock, Julio and Wharton, Sean},
  title = {Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11653--11663},
  doi = {10.1111/dom.71323}
}
Kostenlos starten →